$QURE
uniQure N.V.

2023 Q2 Form 10-Q Financial Statement

#000155837023008658 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $2.422M $5.325M $1.792M
YoY Change 387.32% 197.15% 294.71%
Cost Of Revenue $1.352M $2.435M
YoY Change 62.5%
Gross Profit $1.070M $2.890M
YoY Change -419.4%
Gross Profit Margin 44.18% 54.27%
Selling, General & Admin $21.18M $17.85M $10.99M
YoY Change 69.57% 62.45% -11.22%
% of Gross Profit 1979.53% 617.58%
Research & Development $45.80M $60.81M $45.00M
YoY Change -0.85% 35.12% 37.81%
% of Gross Profit 4280.28% 2104.12%
Depreciation & Amortization $2.588M $2.527M $2.122M
YoY Change 30.64% 19.09% 14.09%
% of Gross Profit 241.87% 87.44%
Operating Expenses $66.14M $78.66M $55.99M
YoY Change 12.71% 40.48% 24.34%
Operating Profit -$65.07M -$74.17M -$54.08M
YoY Change 16.08% 37.15% 21.64%
Interest Expense -$3.237M $3.562M $2.515M
YoY Change -220.16% 41.63% 62.15%
% of Operating Profit
Other Income/Expense, Net $0.00 $216.0K $193.0K
YoY Change -100.0% 11.92% -17.17%
Pretax Income -$68.31M -$78.43M -$47.29M
YoY Change 73.47% 65.84% 14.39%
Income Tax $163.0K -$1.207M -$616.0K
% Of Pretax Income
Net Earnings -$68.47M -$77.23M -$46.68M
YoY Change 75.3% 65.45% 12.33%
Net Earnings / Revenue -2827.17% -1450.27% -2604.8%
Basic Earnings Per Share -$1.44 -$1.63 -$1.00
Diluted Earnings Per Share -$1.44 -$1.63 -$1.00
COMMON SHARES
Basic Shares Outstanding 47.58M 46.98M 46.60M
Diluted Shares Outstanding 47.65M 47.44M 46.60M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $628.6M $315.3M $524.9M
YoY Change 25.59% -39.92% 101.26%
Cash & Equivalents $513.6M $153.9M $524.9M
Short-Term Investments $115.0M $161.5M
Other Short-Term Assets $15.60M $15.04M $14.68M
YoY Change -6.62% 2.4% 113.22%
Inventory $10.21M $7.477M
Prepaid Expenses $12.35M $12.57M $12.42M
Receivables $102.6M $104.8M $38.64M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $757.0M $442.6M $578.2M
YoY Change 44.65% -23.45% 104.8%
LONG-TERM ASSETS
Property, Plant & Equipment $79.96M $50.07M $44.92M
YoY Change 73.89% 11.47% 32.65%
Goodwill $26.02M $26.00M $26.57M
YoY Change 4.16% -2.13% 5028.38%
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change
Other Assets $20.12M $6.121M $5.937M
YoY Change 236.78% 3.1% -68.59%
Total Long-Term Assets $185.8M $188.4M $178.9M
YoY Change 4.44% 5.27% 119.49%
TOTAL ASSETS
Total Short-Term Assets $757.0M $442.6M $578.2M
Total Long-Term Assets $185.8M $188.4M $178.9M
Total Assets $942.8M $631.0M $757.2M
YoY Change 34.45% -16.66% 108.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.373M $8.885M $9.920M
YoY Change -6.53% -10.43% 72.55%
Accrued Expenses $31.32M $22.53M $19.95M
YoY Change 35.88% 12.96% -4.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $68.36M $66.34M $44.70M
YoY Change 41.64% 48.4% 39.24%
LONG-TERM LIABILITIES
Long-Term Debt $473.6M $103.3M $101.4M
YoY Change 364.77% 1.81% 43.93%
Other Long-Term Liabilities $40.74M $958.0K $3.439M
YoY Change 1066.22% -72.14% 10.69%
Total Long-Term Liabilities $514.3M $151.9M $166.4M
YoY Change 208.95% -8.74% 61.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $68.36M $66.34M $44.70M
Total Long-Term Liabilities $514.3M $151.9M $166.4M
Total Liabilities $589.4M $218.2M $211.1M
YoY Change 174.52% 3.35% 56.22%
SHAREHOLDERS EQUITY
Retained Earnings -$727.6M -$659.2M -$501.8M
YoY Change 34.53% 31.35% -39.27%
Common Stock $2.877M $2.869M $2.821M
YoY Change 1.91% 1.7% 1.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $353.3M $412.8M $546.0M
YoY Change
Total Liabilities & Shareholders Equity $942.8M $631.0M $757.2M
YoY Change 34.45% -16.66% 108.09%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$68.47M -$77.23M -$46.68M
YoY Change 75.3% 65.45% 12.33%
Depreciation, Depletion And Amortization $2.588M $2.527M $2.122M
YoY Change 30.64% 19.09% 14.09%
Cash From Operating Activities -$57.00M -$78.30M -$25.71M
YoY Change 263.55% 204.55% -37.71%
INVESTING ACTIVITIES
Capital Expenditures $1.074M $2.342M $4.058M
YoY Change -123.45% -42.29% 4.7%
Acquisitions $822.0K
YoY Change
Other Investing Activities $46.90M $5.330M -$822.0K
YoY Change -748.42%
Cash From Investing Activities $45.83M $2.988M -$4.880M
YoY Change -1100.87% -161.23% 25.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 370.1M 131.0K 485.0K
YoY Change 638067.24% -72.99% -99.23%
NET CHANGE
Cash From Operating Activities -57.00M -78.30M -25.71M
Cash From Investing Activities 45.83M 2.988M -4.880M
Cash From Financing Activities 370.1M 131.0K 485.0K
Net Change In Cash 359.0M -74.15M -31.27M
YoY Change -1877.17% 137.09% -297.32%
FREE CASH FLOW
Cash From Operating Activities -$57.00M -$78.30M -$25.71M
Capital Expenditures $1.074M $2.342M $4.058M
Free Cash Flow -$58.07M -$80.64M -$29.77M
YoY Change 423.21% 170.9% -34.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47546673
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46968032
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47436335
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46599114
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001590560
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36294
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
uniQure N.V.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Paasheuvelweg 25
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
1105 BP
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Amsterdam
CY2023Q1 dei Entity Address Country
EntityAddressCountry
NL
CY2023Q1 dei City Area Code
CityAreaCode
31
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
20-240-6000
CY2023Q1 dei Security12b Title
Security12bTitle
Ordinary Shares, par value €0.05
CY2023Q1 dei Trading Symbol
TradingSymbol
QURE
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47583959
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
153851000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228012000
CY2023Q1 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
161487000
CY2022Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
124831000
CY2023Q1 qure Accounts Receivable And Contract With Customer Asset Current
AccountsReceivableAndContractWithCustomerAssetCurrent
104793000
CY2022Q4 qure Accounts Receivable And Contract With Customer Asset Current
AccountsReceivableAndContractWithCustomerAssetCurrent
102376000
CY2023Q1 us-gaap Inventory Net
InventoryNet
7477000
CY2022Q4 us-gaap Inventory Net
InventoryNet
6924000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
12567000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11817000
CY2023Q1 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
2468000
CY2022Q4 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
2814000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
442643000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
476774000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
46900000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
44100000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50072000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50532000
CY2022Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent
39984000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32135000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32726000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
59704000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
58778000
CY2023Q1 us-gaap Goodwill
Goodwill
25998000
CY2022Q4 us-gaap Goodwill
Goodwill
25581000
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
14331000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
14528000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6121000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6061000
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
188361000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
228190000
CY2023Q1 us-gaap Assets
Assets
631004000
CY2022Q4 us-gaap Assets
Assets
704964000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
8885000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10984000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22529000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30571000
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
27253000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
25982000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7669000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8382000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
66336000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
75919000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
103253000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
102791000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
31075000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
31719000
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
9641000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
9334000
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
6970000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
8257000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
958000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
935000
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
151897000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
153036000
CY2023Q1 us-gaap Liabilities
Liabilities
218233000
CY2022Q4 us-gaap Liabilities
Liabilities
228955000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47546673
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46968032
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
2869000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2838000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1121554000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1113393000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-52494000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-58291000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-659158000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-581931000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
412771000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
476009000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
631004000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
704964000
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5325000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1792000
CY2023Q1 qure Cost Of Contract Manufacturing Revenues
CostOfContractManufacturingRevenues
2435000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60809000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45003000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17848000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10987000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
81092000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
55990000
CY2023Q1 us-gaap Other Income
OtherIncome
1811000
CY2022Q1 us-gaap Other Income
OtherIncome
311000
CY2023Q1 us-gaap Other Expenses
OtherExpenses
216000
CY2022Q1 us-gaap Other Expenses
OtherExpenses
193000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-74172000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-54080000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1669000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
42000
CY2023Q1 us-gaap Interest Expense
InterestExpense
3562000
CY2022Q1 us-gaap Interest Expense
InterestExpense
2515000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2369000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
8567000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
692000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-78434000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47294000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1207000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-616000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-77227000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46678000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
5797000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-10450000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71430000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57128000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.63
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.63
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47436335
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46599114
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
595776000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46678000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-10450000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
424000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6868000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
61000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
546001000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
476009000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-77227000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5797000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
87000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8061000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
44000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
412771000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-77227000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-46678000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2527000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2122000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8061000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6868000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1207000
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-616000
CY2023Q1 qure Change In Fair Value Of Derivative Financial Instruments And Contingent Consideration
ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration
975000
CY2022Q1 qure Change In Fair Value Of Derivative Financial Instruments And Contingent Consideration
ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration
1512000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-1193000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
7356000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
469000
CY2023Q1 qure Increase Decrease In Accounts Receivable And Contract Assets Prepaid Expenses And Other Current Assets And Receivables
IncreaseDecreaseInAccountsReceivableAndContractAssetsPrepaidExpensesAndOtherCurrentAssetsAndReceivables
936000
CY2022Q1 qure Increase Decrease In Accounts Receivable And Contract Assets Prepaid Expenses And Other Current Assets And Receivables
IncreaseDecreaseInAccountsReceivableAndContractAssetsPrepaidExpensesAndOtherCurrentAssetsAndReceivables
-17209000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
553000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1661000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7306000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-9005000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6078000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78302000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25711000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2342000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4058000
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
5330000
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
822000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2988000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4880000
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
131000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
485000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
131000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
485000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1034000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1168000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-74149000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31274000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
231173000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
559353000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
157024000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
528079000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
153851000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
524886000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3173000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3193000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
157024000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
528079000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
3057000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1906000
CY2023Q1 qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
-753000
CY2022Q1 qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
-611000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1</b></span>General business information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">uniQure N.V. (the “Company”) was incorporated on January 9, 2012, initially as a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company’s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics Holding N.V (“AMT”). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering on the Nasdaq Global Select Market, the Company converted into a public company with limited liability (<i style="font-style:italic;">naamloze vennootschap</i>) and changed its legal name from uniQure B.V. to uniQure N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 1pt 0pt 1pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is registered in the trade register of the Chamber of Commerce (<i style="font-style:italic;">Kamer van Koophandel</i>) in Amsterdam, the Netherlands under number 54385229. The Company’s headquarters are in Amsterdam, the Netherlands, and its registered office is located at Paasheuvelweg 25a, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol “QURE”.</p>
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.3</b></span><b style="font-weight:bold;">Use of estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2023Q1 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
161487000
CY2023Q1 qure Debt Securities Current Held To Maturity Accumulated Unrecognized Loss
DebtSecuritiesCurrentHeldToMaturityAccumulatedUnrecognizedLoss
277000
CY2023Q1 us-gaap Debt Securities Current
DebtSecuritiesCurrent
161210000
CY2022Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
164815000
CY2022Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
326000
CY2022Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
164489000
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
27300000
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
36900000
CY2023Q1 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
10929000
CY2022Q4 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
11120000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9350000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17201000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2250000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2250000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22529000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30571000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
12300000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2021Q3 us-gaap Deferred Compensation Arrangement With Individual Requisite Service Period1
DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
P1Y
CY2022 us-gaap Deferred Compensation Arrangement With Individual Requisite Service Period1
DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
P3Y
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.015
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.258
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.013
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7923637
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6428412

Files In Submission

Name View Source Status
qure-20230331_def.xml Edgar Link unprocessable
0001558370-23-008658-index-headers.html Edgar Link pending
0001558370-23-008658-index.html Edgar Link pending
0001558370-23-008658.txt Edgar Link pending
0001558370-23-008658-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
qure-20230331.xsd Edgar Link pending
qure-20230331x10q.htm Edgar Link pending
qure-20230331xex10d1.htm Edgar Link pending
qure-20230331xex31d1.htm Edgar Link pending
qure-20230331xex31d2.htm Edgar Link pending
qure-20230331xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
qure-20230331_cal.xml Edgar Link unprocessable
qure-20230331_pre.xml Edgar Link unprocessable
qure-20230331_lab.xml Edgar Link unprocessable
qure-20230331x10q_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending